Overview
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
Description
Age-related macular degeneration (AMD) is the most frequent cause of blindness in industrialized countries. Multiple molecular pathways have been implicated in the pathogenesis of choroidal neovascularization (CNV). Currently, the treatment relies on neutralization of VEGF (Vascular Endothelial Growth Factor). However some patients have an incomplete response to anti-VEGF treatment. A recent study suggested the implication of the mineralocorticoid receptor pathway in the formation of CNV.
The study (of investigators) aim is to evaluate the concentation of metabolites of MR pathway in the blood and aqueous humor of patients with CNV and compared them with patients without CNV in order to increase our understanding of CNV pathogenesis and find potential biomarker of response to anti-VEGF treatment.
Eligibility
Inclusion Criteria:
Patients of group 1:
- Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration
- Patients without intravitreal injection or last intravitreal injection \> 3 months
- Informed signed consent
Patients of group 2:
- Patients without choroidal neovascularization
- Patients with intraocular surgery (cataract or vitrectomy surgery)
- Signed consent
Exclusion Criteria:
- Myocardial infarction \< 12 months
- Chronic renal failure
- Inflammatory disease
- Infectious disease :HIV, viral hepatitis, tuberculosis
- Type 1 or 2 Diabetes
- Patients treated by mineralocorticoid antagonist treatment.
- Type 2 or 3 choroidal neovascularization
- Pregnant woman
